

研究成果の刊行に関する一覧表レイアウト

雑誌

発表者氏名	論文タイトル名	発表誌名	出版年	巻号	ページ
Yang JC, Wu YL, Chan V, Kurnianda J, <u>Nakagawa K</u> , Saijo N, Fukuoka M, McWalter G, McCormack R, Mok TS.	Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS).	Lung Cancer.	2013	S0169-5002(13)	00535-00537
○ Tsuya A, <u>Kurata T</u> , Tamiya A, Okamoto I, Ueda S, Sakai D, Sugimoto N, Matsumoto K, Goto I, Yamamoto N, Fukuoka M, <u>Nakagawa K</u> .	A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary site.	Invest New Drugs.	2013	31(6)	1568-1572
Kawakami H, Okamoto I, Okamoto W, Takeda M, Ueda S, Kudo T, Nishina S, Fujisaka Y, Miyazaki M, Tsurutani J, <u>Kurata T</u> , <u>Nakagawa K</u> .	Practical Use of Gemcitabine and Cisplatin Combination Therapy as First-Line Treatment for Japanese Patients with Advanced Biliary Tract Cancer.	Journal of Cancer Therapy.	2013	4	1068-1073
Shaw AT, Kim DW, <u>Nakagawa K</u> , Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Jänne PA.	Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.	N Engl J Med.	2013	368(25)	2385-2394
Seto T, Kiura K, Nishio M, <u>Nakagawa K</u> , Maemondo M, Inoue A, Hida T, Yamamoto N, Yoshioka H, Harada M, Ohe Y, Nogami N, Takeuchi K, Shimada T, Tanaka T, Tamura T.	CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.	Lancet Oncol.	2013	14(7)	590-598
Yoshioka H, Okamoto I, Morita S, Ando M, Takeda K, Seto T, Yamamoto N, Saka H, Atagi S, Hirashima T, Kudoh S, Satouchi M, Ikeda N, Iwamoto Y, Sawa T, Nakanishi Y, <u>Nakagawa K</u> .	Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study.	Ann Oncol.	2013	24(5)	1326-1331
○ Kurahashi I, <u>Fujita Y</u> , Arao T, <u>Kurata T</u> , Koh Y, <u>Sakai K</u> , Matsumoto K, Tanioka M, Takeda K, Takiguchi Y, Yamamoto N, Tsuya A, Matsubara N, Mukai H, Minami H, Chayahara N, Yamanaka Y, Miwa K, Takahashi S, Takahashi S, <u>Nakagawa K</u> , <u>Nishio K</u> .	A microarray-based gene expression analysis to identify diagnostic biomarkers for unknown primary cancer.	PLoS One.	2013	8(5)	e63249
Ogi S, Fujita H, Kashiwara M, Yamamoto C, Sonoda K, Okamoto I, <u>Nakagawa K</u> , Ohdo S, Tanaka Y, Kuwano M, Ono M.	Sorting nexin 2-mediated membrane trafficking of c-Met contributes to sensitivity of molecular targeted drugs.	Cancer Science	2013	104(5)	573-583
Kawakami H, Okamoto I, Arao T, Okamoto W, Matsumoto K, Taniguchi H, Kuwata K, Yamaguchi H, <u>Nishio K</u> , <u>Nakagawa K</u> , Yamada Y.	MET amplification as a potential therapeutic target in gastric cancer.	Oncotarget.	2013	4(1)	9-17
Hayashi H, Tsurutani J, Satoh T, Masuda N, Okamoto W, Morinaga R, Terashima M, Miyazaki M, Okamoto I, Nishida Y, Tominaga S, Tokunaga Y, Yamaguchi M, Sakamoto J, Nakayama T, <u>Nakagawa K</u> .	Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B.	Breast Cancer.	2013	20(2)	131-136